Tag Archives: Adverum Biotechnologies

Chardan Capital Keeps a Buy Rating on Adverum Biotechnologies (ADVM)

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) on May 5 and set a price target of $20.00. The company’s shares closed last Friday at $19.59. According to TipRanks.com, Amusa is a

Adverum Biotechnologies (ADVM) Receives a Buy from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today. The company’s shares closed last Monday at $11.07. According to TipRanks.com, Amusa is a top 100 analyst with an average return of 22.2%

Adverum Biotechnologies (ADVM) Gets a Buy Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) yesterday and set a price target of $20.00. The company’s shares closed last Monday at $10.50. According to TipRanks.com, Amusa is a top 100

Cowen & Co. Maintains Their Buy Rating on Adverum Biotechnologies (ADVM)

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The company’s shares closed last Monday at $7.94. According to TipRanks.com, Nadeau is a 5-star analyst with an

Chardan Capital Sticks to Its Hold Rating for Adverum Biotechnologies (ADVM)

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $12. Amusa observed: “We note the “positive” OPTIC results

Adverum Biotechnologies (ADVM) Gets a Hold Rating from Chardan Capital

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Adverum Biotechnologies (ADVM – Research Report) today and set a price target of $10. The company’s shares closed last Monday at $13.40. According to TipRanks.com, Amusa is a 5-star analyst